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Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296 S87Purpose: Osteoarthritis is degenerative joint disease that leads to
permanent joint damage and is a multi-factorial complex disease. It is
well established that in OA cartilage and synovium that some of the
metalloproteinases (MMP) are over expressed including MMP- 2, 9 and
13 and Tissue inhibitors of Matrix metalloproteinases (TIMP) are down
regulated. There is currently great interest in the ﬁeld of OA to identify
biomarkers that provide a method for earlier diagnosis and identify
patients at higher risk for disease progression. This study was designed
to test the hypothesis that plasma levels of gelatinase(s) MMP-2 and 9
predict knee OA severity and progression based on radiographic
ﬁndings.
Methods: 150 Symptomatic knee OA (SKOA) patients (mean age 63.09 
10.3, mean BMI 26.5  3.6) fulﬁlling ACR criteria for knee OA were
recruited as part of an NIH-funded 24 month prospective study. These
patients were followed longitudinally for 24 months, x-ray were taken at
visit 0 and 24 months. The blood samples were collected at baseline and
every 6 months. Standardized semi-ﬂexed radiographs were scored for
overall Kellgren and Lawrence (KL) grade, osteophytes, joint space width
(JSW) and subchondral sclerosis by the same radiologist. Plasma samples
from visit 18 month of 128 OA patients (37% male) were assayed for
gelatinase(s) MMP-2 and 9 using the highly sensitive Erenna Immunoassay
system (Singulex, Inc). For radiographic severity, biomarker were evalu-
ated between KL scores of 1, 2 with those with scores of 3, 4. Progression of
knee OA was deﬁned as a change between baseline and 24 month visit in
narrowest joint space width (JSW) in signal knee.
Results: The mean plasma MMP2 and 9 (pro and total) levels were 83.0 
63.05 ng/ml, 30.7  32.64 and 455.9  290.09 (all ng/mL), respectively.
Only total MMP-9 positively correlated with KL score both at baseline
(r¼0.220; p<0.036) and 24 (r¼0.249; p<0.015) month. MMP-2 or
proMMP9 levels did not correlate with either radiographic marker. We
further analyzed association of tMMP9 level with radiographic severity
and progression by JSN as deﬁned in the methods. tMMP9 correlated with
radiographic severity (p<0.061) at baseline, and with progressive joint
space narrowing (r¼ 0.228; p<0.015). However, we did not observe
signiﬁcant association between tMMP9 and delta KL score in this 24month
study.
Conclusions: These ﬁndings indicate that elevated levels of total gelati-
nase -9 (tMMP9) are associated with radiographic severity of SKOA and
predict an increased risk of progressive joint space narrowing (JSN). These
observations, which suggest that tMMP9 is a candidate prognostic
biomarker, merit further validation in larger cohort of SKOA patients.160
STRUCTURAL PROGRESSION OF ANKYLOSING SPONDYLITIS IS
ASSOCIATED WITH ELEVATION IN TWO NOVEL, INFLAMMATORY
BIOMARKERS; MATRIX METALLOPROTEINASE AND CATHEPSIN-
DERIVED CRP
A.C. Bay-Jensen 1, H. Skjøt-Arkil 1, M.A. Karsdal 1, D.J. Leeming 1,
W.P. Maksymowych 2, S. Wichuk 2, P. Qvist 1. 1Nordic BioSci., Herlev,
Denmark; 2Univ. of Alberta, Div. of Rheumatology, Edmonton, AB, Canada
Purpose: Ankylosing Spondylitis (AS) is a chronic inﬂammatory disease,
however current inﬂammatory biomarkers, such as CRP, have insufﬁcient
sensitivity and speciﬁcity to be broadly accepted in the diagnosis and
prognosis of this disease. We hypothesized, that quantiﬁcation of inﬂam-
mation markers derived from the affected tissue might have improved
clinical utility compared to the systemic markers, and we therefore
developed two novel biomarker assays detecting MMP and Cathepsin-
derived CRP. Both CRP-MMP and CRP-CAT has been reported to be elevated
in AS compared to controls (Skjøt-Arkil et al., in print), whereas full-length
CRP was not.
The purpose of the present study was to determine, in a larger, second
cohort of patients with AS, the clinical utility of CRP-MMP and CRP-CAT
including (1) diagnostic sensitivity & speciﬁcity, (2) association with long-
term radiological changes in the spine (modiﬁed Stoke AS Spinal Score
(mSASSS)), and (3) sensitivity to anti-TNF treatment.
Methods: Cohort 1; Serum samples (n¼124) obtained from patients
diagnosed with AS was available for this study. Mean duration of diseasewas 18,0+11,4 years (mean+SD) and they had received 2.3+9.7 months of
anti-TNF treatment before study entry.
Within this cohort, samples from 16 AS patients with structural progres-
sion over two years and 29 without were selected for evaluation of the
prognostic value of the marker set (sub-cohort 1A). Structural progression
was achieved in subjects having a baseline mSASSS of at least 10 units
increasing with at least 5 units over two years, and simultaneously the
occurrence of at least one new syndesmophyte.
Sub-cohort 1B contained samples from 53 AS patients from cohort 1, and
these originated from patients who subsequently received anti-TNF
treatment for three months and was then re-tested with the marker panel.
Finally, we included serum samples (n¼40) from healthy subjects as
additional controls (Cohort 2).
Serum samples were tested for CRP-MMP and CRP-CAT (Nordic Bioscience,
Denmark).
Results: For baseline evaluations, data from cohort 1 and 2 were used.
CRP-MMP and CRP-CAT were both elevated in AS compared to controls;
9.84+4.40 ng/ml (mean+SD) vs 4.82+1.49 ng/ml (p<0.05), respectively, for
CRP-MMP; and 299.6+137.6 ng/ml vs 178.6+54.03 ng/ml (p<0.05), for CRP-
MMP. Diagnostic capability was assessed by ROC analysis, and AUC was
0.94 (p<0.0001) and 0.85 (p<0.0001) for CRP-MMP and CRP-CAT,
respectively.
In AS patients with structural progression over two years (sub-cohort 1A),
CRP-MMP and CRP-CAT were signiﬁcantly elevated at baseline compared
to non-progressors, whereas hsCRP was not; 9.2+3.1 ng/ml vs 7.6+2.2 ng/
ml for CRP-MMP, 276+108 ng/ml vs 218+67 ng/ml for CRP-CAT, and
21.9+25.6 ng/ml vs 12.7+21.5 ng/ml for hsCRP, respectively.
Finally, both CRP-related markers decreased signiﬁcantly after short term
(2-3 months) of anti-TNF treatment (sub-cohort 1B).
Conclusions: In a second, much larger cohort of AS patients, we have
conﬁrmed the original observation, that MMP and Cathepsin-derived
fragments of CRP, i.e. CRP-MMP and CRP-CAT, both are signiﬁcantly
elevated in AS patients. Importantly, both markers, but not hsCRP, were
signiﬁcantly elevated at baseline in patients having structural progression
deﬁned by a composite index including mSASSS and syndesmophyte
quantiﬁcation.
Further studies are needed to determine if the suggested association of the
two CRP-fragments with structural deterioration of AS reﬂects a metabolic
link to pathological processes in the spine.
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ADIPOKINES AND (VERY) EARLY-STAGE OSTEOARTHRITIS BURDEN AND
PROGRESSION OF KNEE AND HIP: DATA FROM CHECK
W.E. van Spil, N.W. Jansen, S.C. Mastbergen, J.W. Bijlsma, F.P. Lafeber. Univ.
Med. Ctr. Utrecht, Utrecht, Netherlands
Purpose: To investigate the potential relevance of adipokines in the
development and/or progression of (very) early knee and hip osteoarthritis
(OA).
Methods: Adipokine levels were related to serum and urinary biomarkers
of cartilage and synovial metabolism as well as radiographic OA burden
and 5-year progression
Baseline plasma leptin, adiponectin, and resistin levels were assessed by
ELISA in samples from CHECK (Cohort Hip & Cohort Knee), a prospective
cohort of 1002 individuals with symptoms of (very) early knee and/or hip
OA.
Baseline biomarkers of cartilage and synovial metabolism were assessed
by ELISA or RIA (Cartilage: uCTX-II, sPIIANP, sCS846. Synovial tissue: sHA,
sPIIINP. Cartilage/synovial tissue: sCOMP).
Knee and hip radiographs were obtained at baseline and after 2 and 5
years. OA burdenwas expressed as the summed Kellgren & Lawrence (K&L)
score for knees and hips at baseline. OA progression was expressed as the
area under the curve (AUC) of the summed K&L scores.
Associations were investigated through multiple linear regression and
binary logistic regression (OA burden: summed K&L grade 0 vs >1,
progression: AUC 0 vs >0).
Results: Data were complete for approximately 800 participants at base-
line and 725 participants at all time points. Baseline summed K&L grades 0,
1, 2, 3, and 4 were present in 33.9, 26.8, 24.0, 9.6, and 5.7% of participants,
respectively (maximum K&L grade for individual joints¼1). AUC of
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and 5.5-17.5 for 39.0, 18.3, 22.5, and 20.1% of participants, respectively.
pLeptin was positively associated with pResistin (stand beta 0.115,
P¼0.000) and negatively with pAdiponectin (stand beta -0.080, P¼0.012),
other associations between adipokines were not statistically signiﬁcant.
pLeptin showed statistically signiﬁcant associations with sPIIANP and
sPIIINP (stand betas 0.050, P¼0.01 and 0.056, P¼0.005, adjusted for age,
BMI, and gender). pLeptin showed a statistically signiﬁcant association
with OA progression before adjustment (stand beta 0.099, P¼0.007), that
turned non-signiﬁcant after adjustment for demographic variables (stand
beta -0.006, P¼0.917).
pAdiponectin was statistically signiﬁcantly associated with sCOMP only
(stand beta 0.105, P¼0.001, adjusted) and not associated with OA burden
and progression (data not shown).
pResistin showed a statistically signiﬁcant associationwith sPIIINP, sCOMP,
and sC12C (stand betas 0.091, -0.083, and -0.086, respectively, P<0.014)
and was associated with radiographic OA burden (stand beta 0.093,
P¼0.008, adjusted) and progression (in binary logistic regression: (Exp(B)
1.165, P¼0.031, adjusted for age, gender, BMI, and baseline summed K&L
grade. Multiple linear regression: stand beta 0.011, P¼0.769, adjusted).
Conclusions: Leptin and resistin showed the most associations with
biomarkers and radiographic OA burden and progression. Leptin may
function as a humoral mediator between OA progression and demo-
graphics, while resistin also showed an effect on OA burden and
progression apart from the studied demographics. The low grade of all
associations may be partly due to the limitations of biomarkers and
radiographic disease measures in early-stage OA. Nevertheless, these data
indicate that systemic adipokines could be involved in early-stage OA
burden and progression.
This study was funded by CHECK (Cohort Hip & Cohort Knee), an initiative
of the Dutch Arthritis Association.
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COMPARISON OF HEALTHY AND NORMATIVE AGING REVEALS
A METABOLIC COMPONENT IN HAND OA AND OA BIOCHEMICAL
MARKER PROFILES.
S.D. Bos 1,2, M. Beekman 1, R. Westendorp 1, T. de Craen 1,
M. Kloppenburg 1, I. Meulenbelt 1,2, P.E. Slagboom1,2. 1 LUMC, Leiden,
NETHERLANDS; 2 The Netherlands Genomics Initiative-sponsored
Netherlands Consortium for Hlth.y Aging, Leiden, NETHERLANDS
Purpose: Epidemiological studies have shown associations between
osteoarthritis (OA) and age, as well as between OA and metabolism, which
are not completely understood. It can be questioned whether intrinsic
metabolic programming affects OA risk and circulating levels of
biochemical markers applied in OA research such as COMP and CTX2.
These biomarkers measured in serum and urine reﬂect cartilage turnover
and degradation, respectively.
Insight in interactions between age, metabolism and OA will allow for
better clinical classiﬁcation of patients and for a more reliable assessment
of disease activity or progression using biochemical markers. Such insights
may be obtained from studies focused on aging and metabolism, inde-
pendent of disease. To such end, we have analyzed levels of serum COMP
and urinary CTX2 and hand radiographic OA (ROA) scores in healthy aging
subjects from long-lived families, their partners as population controls and
OA patients. We analyzed age related aspects of the biochemical markers
and hand ROA scores and compared the marker and ROA score proﬁles in
healthy and normative aging and in disease. Next we tested whether
glucose levels inﬂuenced the levels of biochemical markers and hand ROA
scores in the healthy and normative aging subjects.
Methods: The Leiden Longevity Study (LLS) consists of long-lived siblings,
their offspring and partners of the offspring as controls. In middle age the
familial longevity trait is reﬂected by a 30% increased survival, low prev-
alence of metabolic disease and healthy metabolic proﬁle (such as lower
glucose levels). We measured uCTX2 and sCOMP levels in a subset of the
females of the LLS (N¼151 healthy agers and N¼181 controls) and scored
hand radiographs (20 joint sites) according to Kellgren and Lawrence
(N¼107 healthy agers and N¼128 controls). The same scores were avail-
able for the OA affected females of the GARP study (N¼315). Furthermore,
these were previously typed for the biochemical marker levels sCOMP anduCTX2. Linear mixed models were applied testing for relationships
between age and hand ROA data or marker levels, whilst correcting for
BMI, familial dependencies and potential batch effects between the GARP
and LLS study.
Results: sCOMP shows a comparable age related increase in healthy and
normative agers as well as in OA patients. Healthy agers, however, had
a signiﬁcantly higher mean sCOMP level as compared to the controls.
Remarkably, uCTX2 levels showed no increase with age in healthy agers
whereas a signiﬁcant and equal age related increase was observed
amongst the controls and OA patients.
Healthy ageing women have the lowest age related increase of hand ROA
score, whereas this has a signiﬁcant linear increase via controls to the OA
patients (study groups coded as 0, 1 and 2 for healthy agers, controls and
GARP patients respectively, BMI and age adjusted). When we additionally
selected the healthy agers with glucose levels below the median within
their group, the interaction of study group with hand ROA scores became
more pronounced between healthy agers and controls.
Conclusions: When interpreting OA biomarkers, age is a major factor to
consider. Furthermore, a healthy aging metabolic proﬁle as reported for
the Leiden longevity family members associated to a lower age-related
increase in hand ROA scores and uCTX2 levels as compared to controls.
This may indicate that metabolic health should also be considered in the
assessment of the risk for hand ROA onset and monitoring of progression
on the basis of these biomarkers.
Comp as a new potential biomarker for osteoarthritis.
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20KDa FRAGMENT OF OSTEOGLYCIN: AN INNOVATIVE TOOL FOR OA
PATIENTS CHARACTERIZATION
A. Farran, L. Tio, P. Benito, J. Monfort. IMIM-Hosp. del Mar, Barcelona, Spain
Purpose: Osteoarthritis is the most common rheumatologic disease and is
characterized by increased protease activity resulting in cartilage degra-
dation. Nowadays, radiographic measures are the traditional study for
diagnosis, but the abnormal metabolic process begins in the articular
cartilage several years before destruction of the tissue can be detected
radiologically. Our aim in this study is the search for new osteoarthritic
molecular biomarkers, by the screening of different ECM proteins and their
fragments in osteoarthritic (OA) and normal cartilage (CT).
Methods: Normal samples were obtained from femoral cartilage of
patients who underwent hip replacement due to osteoporotic fracture. OA
cartilage samples came from knee and hip arthrosic patients undergoing
arthroplasty. ECM proteins from these samples were extracted using
Guanidinium chloride (4 mol/l) method. After the extraction, proteins and
glycosaminoglycans (GAG's) were quantiﬁed by Bradford and dimethyl-
methylene-blue (DMB) assay respectively. Proteoglycans studied from the
ECM protein extracts of knee and hip cartilage were normalized by Brad-
ford concentration and analyzed by Western blotting. The bands intensity
was quantiﬁed by Quantity One software. In order to study the activity of
the protease in front of each proteoglycan studied and to ﬁnd out speciﬁc
fragments from OA patients, the extracts were digested with recombinant
matrix metalloproteinase 13 (MMP-13) at 2, 4, 6, 8, 16 and 24h and
analyzed with western blot.
Results: Osteoglycin (OGN), Matrilin3 (MATN3), and Cartilage oligomeric
matrix protein (COMP) were identiﬁed by Western Blotting. Our results
showed that MATN3 expression did not present any difference between
CT, OA hip and OA knee cartilage.
We could observe digestion of MATN3 by MMP-13 after 6 hours of incu-
bation and it was nearly completely digested at 24h.
In the case of COMP expression, the analysis showed a different band
pattern in OA knee samples compared with CT and OA femoral samples.
Interestingly, a COMP fragment of approximately 60 KDa was observed at
16h and 24h of incubation in all the samples.
Regarding the OGN results, we surprisingly found that it was more
abundant in OA knee samples than in CT ones, contrary to other previously
described proteoglycans observations. Concerning to OGN digestion, we
could also see differences between samples; while OGN from CT samples
was completely digested at 16h, OGN from OA femoral samples showed
still a weak band at 16h of digestion that was completely digested at 24h.
Finally, in OA knee samples, at 24 hours the digestions was not still
